Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by CancerSlayeron Sep 05, 2024 7:39pm
210 Views
Post# 36210896

RE:RE:RE:RE:RE:RE:RE:General question for the board

RE:RE:RE:RE:RE:RE:RE:General question for the board
Imagine the reality of being cancer-free after one TLT treatment.  Imagine the potential for an even better response rate (complete & durable) if giving additional "booster" doses of our drug.  Imagine the potential of giving intravesical Ruvidar in combination with systemic Rutherrin.  Imagine the potential of giving our drug/ACT in combination with other promising immunotherapies (oncolytic/virus-assisted or otherwise).  Imagine activation of Ruvidar/Rutherrin by a less invasive means.  Imagination gone wild...

<< Previous
Bullboard Posts
Next >>